Friday, October 31, 2014 Last update: 1:33 PM
FreshNews.com - Covering Large & Obscure Tech Companies Since 1996

Anacor Pharmaceuticals to Present at the Jefferies 2014 Global Healthcare Conference

Companies mentioned in this article: Anacor Pharmaceuticals, Inc.

PALO ALTO, Calif. -- (BUSINESS WIRE) -- Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) announced today that Paul Berns, the company’s President and Chief Executive Officer, will provide a company overview at the Jefferies 2014 Global Healthcare Conference on Monday, June 2, 2014 at 3:30 p.m. ET in New York, New York. The event will be webcast live and may be accessed under “Events and Presentations” on the Investors page of Anacor’s website at www.anacor.com. A replay will also be available for three months following the presentation.

About Anacor Pharmaceuticals

Anacor is a biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. Anacor’s two lead investigational product candidates are topically administered dermatologic compounds — Kerydin, a topical antifungal in development for the potential treatment of mild-to-moderate onychomycosis of the toenail, and AN2728, an anti-inflammatory PDE-4 inhibitor in development for the potential treatment of mild-to-moderate atopic dermatitis. In addition to its two lead product candidates, Anacor has discovered three other wholly-owned clinical product candidates — AN2718 and AN2898, which are backup compounds to Kerydin and AN2728, respectively, and AN3365, an investigational antibiotic in development for the treatment of infections caused by Gram-negative bacteria. Anacor has also discovered three other compounds that have been out-licensed for further development — one is licensed to Eli Lilly and Company for development in animal health, the second compound, AN5568, also referred to as SCYX-7158, is licensed to Drugs for Neglected Diseases initiative, or DNDi, and is in development for the potential treatment of human African trypanosomiasis (HAT, or sleeping sickness), and the third compound is licensed to GlaxoSmithKline, LLC for development as a potential treatment for tuberculosis. Anacor also has a pipeline of other internally discovered topical and systemic boron-based compounds in earlier stages of research and pre-clinical development. For more information, visit http://www.anacor.com.


Copyright © Business Wire 2014
Contact:

Anacor
DeDe Sheel, 650-543-7575
Senior Director, Investor Relations and Corporate Communications